Ocrelizumab alters the circulating metabolome in people with relapsing-remitting multiple sclerosis.
Fatemeh SiavoshiDimitrios Christos LadakisAshley MullerBardia NourbakhshPavan BhargavaPublished in: Annals of clinical and translational neurology (2024)
In this longitudinal observational study, using a global untargeted metabolomics approach, we showed significant alteration in circulating metabolome in RRMS patients undergoing ocrelizumab treatment. In particular, we observed a significant reduction in metabolites involved in the lysophospholipid pathway, which was associated with patients' improvement.
Keyphrases
- multiple sclerosis
- patients undergoing
- end stage renal disease
- mass spectrometry
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- cross sectional
- disease activity
- rheumatoid arthritis
- liquid chromatography
- high resolution
- patient reported
- combination therapy
- high resolution mass spectrometry